12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Intravenous 31510: Phase I started

Berg LLC, Boston, Mass.
Product: Intravenous 31510 ( BPM 31510)
Business: Cancer
Molecular target: NA
Description: Formulation of ubidecarenone, an endogenous small molecule...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >